Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
| Name (Synonyms) | Correlation |
|---|
| Name (Synonyms) | Correlation |
|---|
Navigate: Correlations HPO
There is one clinical trial.
This is a Phase 1 Randomized, Double-Blind, Parallel Group, Placebo-Controlled Study to Assess the Safety of Ascending Doses of UNI911 INHALATION in Healthy Volunteers in Preparation for Evaluation in Adults with COVID-19
Description: AE frequency in each cohort and treatment group
Measure: Assess safety of UNI911 INHALATION in healthy volunteers: AE frequency Time: Up to Day 6Description: Maximum concentration of active drug molecules in blood (Cmax)
Measure: Pharmacokinetic Parameters: Cmax Time: Up to Day 4 of participant treatmentDescription: Time to reach maximum level (Tmax)
Measure: Pharmacokinetic Parameters: Tmax Time: Up to Day 4 of participant treatmentDescription: Area Under the Curve of drug level in blood versus time (AUC)
Measure: Pharmacokinetic Parameters: AUC Time: Up to Day 4 of participant treatmentDescription: Half life
Measure: Pharmacokinetic Parameters: Half life Time: Up to Day 4 of participant treatmentAlphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports